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Abstract
Background Elderly heart failure (HF) patients are underrepresented in clinical trials, though are a large proportion of 
patients in real-world practice. We investigated practice-based, secondary care HF management in a large group of chronic 
HF patients aged ≥ 80 years (octogenarians).
Methods We analyzed electronic health records of 3490 octogenarians with chronic HF at 34 Dutch outpatient clinics in 
the period between 2013 and 2016 , 49% women. Study patients were divided into HFpEF [LVEF ≥ 50%; n = 911 (26.1%)], 
HFrEF [LVEF < 40%; n = 2009 (57.6%)] and HF with mid-range EF [HFmrEF: LVEF 40–49%; n = 570 (16.3%)].
Results Most HFrEF patients aged ≥ 80 years received a beta blocker and a renin–angiotensin system (RAS) inhibitor 
(angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker), i.e. 78.3% and 72.8% respectively, and a 
mineralocorticoid receptor antagonist (MRA) was prescribed in 52.0% of patients. All three of these guideline-recommended 
medications (triple therapy) were given in only 29.9% of octogenarians with HFrEF, and at least 50% of target doses of 
triple therapy, beta blockers, RAS inhibitor and MRA, were prescribed in 43.8%, 62.2% and 53.5% of the total group of 
HFrEF patients. Contraindications or intolerance for beta blockers was present in 3.5% of the patients, for RAS inhibitors 
and MRAs in, 7.2% and 6.1%
Conclusions The majority of octogenarians with HFrEF received one or more guideline-recommended HF medications. 
However, triple therapy or target doses of the medications were prescribed in a minority. Comorbidities and reported con-
traindications and tolerances did not fully explain underuse of recommended HF therapies.
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Introduction
Elderly patients represent a major proportion of the heart 
failure (HF) population. Most of these elderly patients have 
multiple morbidities [1–3]. This may complicate adherence 
to advocated HF management.
In general, optimizing guideline-recommended HF 
therapies improves quality of life, morbidity and mortal-
ity significantly [4-6]. However, randomized clinical trials 
investigating HF therapies did not represent the real-life HF 
population. The patients enrolled in these trials were on 
average 10 years younger than in real-world practice; elderly 
patients were largely underrepresented and very elderly were 
even excluded, except for the SENIORS-study [7–10].
As such, there are considerable gaps of knowledge in HF 
treatment effects in octogenarians. Practice guidelines do not 
provide age-specific recommendations for implementation 
and utilization of HF therapies [4, 5], but several registries 
reported lower prescription rates of evidence-based medica-
tion in the elderly [11–18]. High age-related factors, e.g., 
frailty, fall risk, cognitive impairment, dementia and dis-
ability, and also polypharmacy and concerns on drug inter-
action may interfere with initiation and persistence of HF 
medication, and as such are potential barriers for optimal 
therapy [5]. Importantly, detailed data regarding prescribed 
HF medication in the very elderly are scarce.
In a large-scale real-world registry at Dutch HF outpatient 
clinics, we investigated medical HF therapies and determi-
nants of prescription of individual HF drugs in a substantial 
group of octogenarians [19, 20], better reflecting contempo-
rary practice-based HF in secondary care.
Methods
The design and methods of the CHECK-HF (Chronisch 
Hartfalen ESC-richtlijn Cardiologische praktijk Kwaliteit-
sproject HartFalen) registry have been published in detail 
earlier [19]. Briefly, the CHECK-HF registry consists of 
10,910 patients with chronic HF from a total of 34 partici-
pating Dutch centers. Between 2013 and 2016, all centers 
included patients diagnosed with HF based on the 2012 ESC 
Guidelines on HF (i.e., based on symptoms and echo param-
eters) who were seen at the outpatient HF clinic (96%) or 
general cardiology outpatient clinic (4%) if no specific HF 
clinic was present.
From electronic health records, baseline patient char-
acteristics, etiology of HF, comorbidities, basic echocar-
diographic and electrocardiographic (ECG) parameters, 
laboratory markers, pacemaker, ICD and CRT treatment as 
well as prescription rates of medication (drug name, dos-
age and frequency and total daily dose) were recorded. The 
target doses of guideline-recommended HF medication are 
presented in Suppl. Table 1. Drug doses were calculated 
compared to the recommended dose and according to guide-
lines as a daily dose or percentage of actual recommended 
daily dose.
Furthermore, contraindications and intolerance as indi-
cated by the treating physician were collected. No predefined 
rules were applied to determine absolute contraindications. 
CHECK-HF is a cross-sectional observational cohort study 
and there were no outcome data collected.
There were 3601 patients aged ≥ 80 years, comprising 
33.1% of the total CHECK-HF cohort.
In 111 (3.1%) patients, recording of ejection fraction or 
age in the database was insufficient to classify patients; so, 
these patients were excluded from this analysis. In the cur-
rent analyses of the remaining 3490 patients, aged ≥ 80 years, 
we focused on the prescribed HF medication.
Based on echocardiographic results, octogenarians were 
divided based on LVEF or visual assessment of the func-
tion of the left ventricle (LV) according to the contemporary 
2016 ESC HF Guidelines into HFpEF [LVEF ≥ 50%; n = 911 
(26.1%)], HFrEF [LVEF < 40%; n = 2009 (57.6%)] and HF 
with mid-range EF [HFmrEF: LVEF 40–49%; n = 570 
(16.3%)].
This study was approved by the medical ethics committee 
2017 at Maastricht University Medical Center (Maastricht, 
the Netherlands). No informed consent of the participants 
in this registry was required.
Statistics
Continuous data are expressed as mean value ± SD or 
median and interquartile range, depending on the distribu-
tion of the data, and compared by applying one-way analysis 
of variances (ANOVA) or Mann–Whitney U-test. Categori-
cal data are expressed as counts and percentages, and com-
pared by the Pearson Chi-square test. A two-sided p value 
of 0.05 was considered statistically significant.
Multivariable predictors for the use of HF medication 
were sought, using multivariable logistic regression analy-
sis, using the stepwise backward procedure. All predictors 
of medication use in univariable analysis (data not shown) 
at a p value of < 0.10 were included in the multivariable 
regression analysis. Results of logistic regression are pre-
sented as odds ratio (ORs). Some missing data occurred in 
the variables included in the multivariable analyses, which 
we corrected using multiple imputation. If the missing 
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variables showed a monotone pattern of missing values, the 
monotone method was used; otherwise, an iterative Markov 
chain Monte Carlo method was used with a number of 10 
iterations. A total of 5 imputations were performed, and the 
pooled data were analyzed. The imputed data were only used 
for the multivariable analysis. For all reported data of the 
multivariable analysis, we compared crude and imputed p 
values as well as the odds ratios and confidence intervals to 
analyze whether imputation changed the results, and if no 
significant changes occurred, we present the imputed values 
in the main analyses.
All analyses were performed with SPSS Statistical Pack-
age version 24.0 (SPSS Inc, Chicago, Illinois).
Results
Baseline characteristics of the 3490 HF patients 
aged ≥ 80 years are shown in Table 1. The median [IQR] 
age was 84 [82.0–87.0] years and 49% were women. Most 
patients were in NYHA class II and approximately half 
of the patients had a ischemic cause of their HF. Median 
Table 1  Characteristics of octogenarians with HF according to LVEF groups (ESC Guidelines 2016)
HF heart failure, LVEF left ventricular ejection fraction, ESC European Society of Cardiology, HFrEF heart failure with reduced ejection frac-
tion, HFmrEF heart failure with mid-range ejection fraction, HFpEF heart failure with preserved ejection fraction, BMI body mass index, NYHA 
New York Heart Association classification, BP blood pressure, LBBB left-bundle branch block, eGFR estimated glomerular filtration rate, 
COPD chronic obstructive pulmonary disease, OSAS obstructive sleep apnea syndrome
Total (n = 3490) HFrEF (n = 2009) HFmrEF (n = 570) HFpEF (n = 911) p value
Age (years) (n = 3490) 84.0 [82.0–87.0] 84.0 [82.0–87.0] 84.0 [82.0–87.0] 85.0 [82.0–88.0]  < 0.01
Men (n = 3475) 1775 (51.1) 1160 (58.0) 290 (51.1) 325 (35.8)  < 0.01
Duration of HF (n = 3480)
  < 1 year 411 (11.8) 222 (11.1) 78 (13.7) 111 (12.2) 0.17
 1–2 years 737 (21.2) 407 (20.3) 126 (22.2) 204 (22.5)
  ≥ 2 years 2332 (67.0) 1376 (68.6) 364 (64.1) 592 (65.3)
 BMI, kg/m2 (n = 3139) 25.0 [23.0–29.0] 25.0 [23.0–28.0] 26.0 [23.0–29.0] 26.0 [24.0–30.0]  < 0.01
NYHA (n = 3440)
 I 335 (9.7) 189 (9.5) 44 (7.8) 102 (11.4) 0.20
 II 1791 (52.1) 1036 (52.3) 310 (55.1) 445 (49.7)
 III 1217 (35.4) 705 (35.6) 195 (34.6) 317 (35.4)
 IV 97 (2.8) 52 (2.6) 14 (2.5) 31 (3.5)
 LVEF, % (n = 2326) 40.0 [30.0–50.0] 30.0 [25.0–35.0] 45.0 [40.0–47.0] 58.0 [52.0–60.0]  < 0.01
Cause of HF (n = 3369)
 Ischemic cause of HF 1518 (45.1) 1061 (54.5) 247 (45.6) 210 (23.8)  < 0.01
 Non-ischemic cause of HF 1851 (54.9) 885 (45.5) 295 (54.4) 671 (76.2)
 Systolic BP, mmHg (n = 3455) 125.0 [111.0–140.0] 122.0 [110.0–139.0] 125.5 [114.3–140.0] 130.0 [118.0–145.0]  < 0.01
 Diastolic BP, mmHg (n = 3461) 70.0 [60.0–76.0] 70.0 [60.0–75.0] 70.0 [60.0–76.0] 70.0 [60.0–79.0] 0.01
 Heart rate, bpm (n = 3446) 70.0 [63.0–80.0] 70.0 [63.0–80.0] 71.0 [62.0–82.0] 70.0 [63.0–80.0] 0.42
 Atrial fibrillation (n = 3445) 1371 (39.8) 666 (33.7) 268 (47.3) 437 (48.4)  < 0.01
 LBBB (n = 3490) 594 (17.0) 432 (21.5) 79 (13.9) 83 (9.1)  < 0.01
 QRS ≥ 130 ms (n = 2830) 1131 (40.0) 786 (48.5) 167 (35.8) 178 (24.0)  < 0.01
 eGFR (n = 2459) 44.2 [32.4–60.6] 45.2 [33.1–61.2] 43.4 [31.6–58.5] 42.0 [31.2–59.6] 0.03
eGFR (n = 2459)
  < 30 498 (20.3) 283 (18.9) 87 (21.6) 128 (22.8) 0.18
 30–59 1324 (53.8) 806 (53.9) 222 (55.2) 296 (52.7)
  ≥ 60 637 (25.9) 406 (27.2) 93 (23.1) 138 (24.6)
Comorbidity (n = 3158)
 Hypertension 1485 (47.0) 763 (42.2) 237 (46.1) 485 (57.9)  < 0.01
 Diabetes mellitus 862 (27.3) 495 (27.4) 139 (27.0) 228 (27.2) 0.98
 COPD 614 (19.4) 326 (18.1) 114 (22.2) 174 (20.8) 0.06
 OSAS 93 (2.9) 51 (2.8) 8 (3.5) 24 (2.9) 0.72
 Thyroid disease 259 (8.2) 153 (8.5) 31 (6.0) 75 (8.9) 0.13
 No relevant comorbidity 148 (5.5) 107 (6.8) 17 (3.8) 24 (3.7)  < 0.01
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[IQR] LVEF was 40% [30.0–50.0], one quarter had diabe-
tes mellitus and the majority (74%) had an eGFR < 60 ml/
min/m2 (Table 1). Several baseline characteristics differed 
significantly between LVEF groups, also when subdividing 
men and women (Suppl. Table 2). HFpEF patients (n = 911) 
were older and more often women, had a higher body mass 
index, more often had a non-ischemic cause of HF, hyperten-
sion, and atrial fibrillation in comparison to HFrEF patients 
(n = 2009). Octogenarians with HFrEF more often had a 
QRS-width ≥ 130 ms and left bundle branch block (LBBB) 
on their ECG, when compared to those with HFpEF, in 
those with sinus rhythm or atrial fibrillation, and not in HF 
patients with paced or ectopic rhythm (Table 1 and Suppl. 
Table 3).
Characteristics of HFmrEF patients aged ≥ 80  years 
(n = 570) did not differ much from those with HFrEF except 
for a higher prevalence of atrial fibrillation and some other 
relevant comorbidities and fewer LBBB on ECG (Table 1). 
COPD was more prevalent in HFmrEF compared to HFrEF 
patients (22.2% and 18.1%, respectively, p = 0.04). HFpEF 
patients had more often hypertension when compared to 
both HFrEF and HFmrEF patients (Fig. 1).
Guideline‑recommended medical therapy in HFrEF
Following the ESC guidelines 2016, a large proportion of 
HFrEF patients aged ≥ 80 years received a beta blocker or a 
RAS inhibitor [angiotensin-converting enzyme (ACE) inhib-
itor or angiotensin receptor blocker (ARB)], i.e., 78.3% and 
72.8%, respectively. An MRA was prescribed in 52.0% of 
patients and diuretics in 90.4%. Women received more often 
a beta blocker and a thiazide diuretic, than men (Table 2).
The combination of all three HF medication (beta 
blocker, RAS inhibitor and MRA), were prescribed to 29.9% 
of HFrEF patients aged ≥ 80 years patients, two out of three 
HF medication in 46.5%, one out of three in 20.3%, and 
none of these medications were prescribed in 3.3% of octo-
genarians with HFrEF. In total, 55 patients (2.7%) received 
ivabradine, which represents 77% of those where ivabradine 
was indicated.
Fig. 1  Comorbidities in octogenarians with heart failure: HFrEF vs. 
HFmrEF vs. HFpEF (ESC Guidelines 2016). HFrEF heart failure 
with reduced ejection fraction, HFmrEF heart failure with mid-range 
ejection fraction, HFpEF heart failure with preserved ejection frac-
tion, ESC European Society of Cardiology, COPD chronic obstruc-
tive pulmonary disease, OSAS obstructive sleep apnea syndrome. 
Renal insufficiency: defined as eGFR < 60  mL/min or a history of 
renal failure
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MRA was less used in patients with more than 2 years of 
follow-up than in those with < 1 year of HF follow-up, 49.0% 
and 61.5% respectively, p < 0.01 (Suppl. Table 4a).
The percentages of target dose of HF medication 
prescribed in the 2009 HFrEF patients (LVEF < 40%) 
aged ≥ 80 years are shown in Fig. 2. At least, 50% of tar-
get doses of beta blockers, RAS inhibitor and MRA were 
prescribed in 43.8%, 62.2% and 53.5% of HFrEF patients, 
respectively (Fig. 2). A ≥ 50% of target dose of all three of 
the HF medications groups was achieved in 9.5% of the 
patients; ≥ 50% of the target dose for two out of three HF 
medications in 35.9%; ≥ 50% of the target dose for one out 
of three HF medications in 39.2%; and ≥ 50% of the target 
dose for none of these HF medications in 15.5%.
The reasons of non-adherence or not prescribing rec-
ommended HF medication (ESC Guidelines 2016) were 
reported by the centers and are depicted in Table 3. Con-
traindications or intolerance for beta blockers was present 
in 3.5% of the patients, for RAS inhibitors, MRAs and 
ivabradine in, respectively, 7.2%, 6.1% and 2.2%. There 
were no substantial differences between men and women 
(Suppl. Table 5). In a substantial number of patients, the 
Table 2  Percentage of HF therapy use in HFrEF, HFmrEF and HFpEF patients aged ≥ 80 years, for men and women
HF heart failure, HFrEF heart failure with reduced ejection fraction, HFmrEF heart failure with mid-range ejection fraction, HFpEF heart fail-
ure with preserved ejection fraction, RAS renin–angiotensin system, RAS inhibitor angiotensin-converting enzyme (ACE) inhibitor or angioten-
sin receptor blocker (ARB), MRA mineralocorticoid receptor antagonists
Guideline-recommended pharmacotherapy Loop diuretics Thiazide diuretics
Beta blocker RAS inhibitor MRA Ivabradine Diuretics
HFrEF Men 879 (76.4) 856 (74.4) 592 (51.4) 32 (2.8) 1035 (89.9) 1,016 (88.3) 20 (1.7)
Women 672 (81.2) 585 (70.7) 438 (52.9) 23 (2.7) 754 (91.1) 731 (88.3) 31 (3.7)
p value 0.01 0.07 0.52 0.98 0.40 0.99 0.01
HFmrEF Men 201 (70.3) 189 (66.1) 131 (45.8) 4 (1.4) 252 (88.1) 244 (85.3) 10 (3.5)
Women 206 (74.6) 191 (69.2) 146 (52.9) 6 (2.2) 255 (92.4) 251 (90.9) 4 (1.4)
p value 0.25 0.43 0.09 0.48 0.09 0.04 0.12
HFpEF Men 226 (70.4) 195 (60.7) 144 (44.9) 4 (1.2) 293 (91.3) 277 (86.3) 16 (5.0)
Women 437 (76.5) 358 (62.7) 253 (44.3) 1 (0.2) 520 (91.1) 506 (88.6) 17 (3.0)
p value 0.04 0.57 0.87 0.06 0.92 0.31 0.13
Fig. 2  Percentages of target dose of HF medication prescribed in 
octogenarians with HFrEF (LVEF < 40%). HF heart failure, HFrEF 
heart failure with reduced ejection fraction, RAS renin–angiotensin 
system, RAS inhibitor angiotensin-converting enzyme (ACE) inhibi-
tor or angiotensin receptor blocker (ARB), MRA mineralocorticoid 
receptor antagonists
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reasons for not receiving recommended HF-medication 
were not specified.
The results of multivariable analysis on guideline-
directed pharmacotherapy in octogenarians with HFrEF 
are presented in Table 4. Lower prescription rates of rec-
ommended RAS inhibitors were associated with higher 
age, NYHA class and heart rate, wider QRS, and also 
HFmrEF (versus HFrEF). Higher prescription rates of 
RAS inhibitors and diuretics were related to hyperten-
sion. Lower prescription of RAS inhibitors but higher use 
of beta blocker was associated with the presence of renal 
failure. MRA use was not associated with these comorbidi-
ties. Prescription rates of recommended HF medication 
were not independently associated with ischemic etiology 
of HF, diabetes mellitus 2 and COPD.
Digoxin was prescribed in one fifth of elderly HFrEF 
patients (21.4%), amiodarone in 7.7% and statins in 69.8%. 
Polypharmacy including beta blocker, RAS inhibitor, 
MRA, ivabradine, diuretics, statin, digoxin and amiodar-
one, median 4 of these drugs, was only slightly related to 
prescription of recommended beta blocker, RAS inhibitor 
and MRA (Suppl. Table 6).
Medical treatment of HFmrEF patients
In the 570 patients with HFmrEF aged ≥ 80 years, beta 
blockers, RAS inhibitor and MRA were prescribed in 72.5%, 
67.6% and 49.1% of elderly HFmrEF patients, respectively. 
These proportions did not differ much from those in HFrEF 
patients (Table 2). Also, the percentages of the combined 
beta blocker, RAS inhibitor and/or MRA use in HFmrEF 
patients, aged ≥ 80 years, were only slightly lower than in 
HFrEF octogenarians, for men and women (Fig. 3). Statins, 
digoxin and amiodarone were prescribed in 66.3%, 22.0% 
and 5.4% of HFmrEF patients, respectively.
Medical treatment of HFpEF patients
In the 911 HFpEF patients aged ≥ 80 years, diuretics were 
used by most frequently (91.2%), followed by beta block-
ers (74.3%), RAS inhibitors (62.0%) and MRAs (44.6%). 
Proportions of beta blockers, RAS inhibitors, MRA and 
diuretics did not differ much from those in HFrEF patients. 
Table 3  Reasons for not prescribing HF medication in HFrEF 
patients aged ≥ 80 years
HF heart failure, HFrEF heart failure with reduced ejection fraction, 
RAS renin–angiotensin system, RAS inhibitor angiotensin-converting 
enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), MRA 
mineralocorticoid receptor antagonists
a If indicated (n = 19) 25.7% of patients did not receive ivabradine 
with no specified reason
Contraindicated or 
intolerance
No reason specified
Beta blocker 69 (3.5) 287 (14.4)
RAS inhibitors 145 (7.2) 396 (19.9)
MRA 121 (6.1) 834 (41.9)
Ivabradinea 43 (2.2) 1891 (95.1)
Table 4  Multivariable 
predictors of the use of HF 
medication in HFrEF patients 
aged ≥ 80 years
HF heart failure, HFrEF heart failure with reduced ejection fraction, RAS renin–angiotensin system, RAS 
inhibitor angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), MRA 
mineralocorticoid receptor antagonists, OR odds ratio, BMI body mass index, BP blood pressure, NYHA 
New York Heart Association classification, eGFR estimated glomerular filtration rate, COPD chronic 
obstructive pulmonary disease, – variable not included in the model
Beta blocker RAS inhibitor MRA Diuretics
OR OR OR OR
Female gender 1.31 [1.02–1.68] – – –
Age (per 10 years) – 0.63 [0.48–0.83] – –
BMI (kg/m2) – – – 1.06 [1.01–1.12]
Systolic BP (per 10 mmHg) – 1.09 [1.02–1.16] 0.80 [0.75–0.85] –
Diastolic BP (per 10 mmHg) – – – 0.77 [0.63–0.93]
NYHA class (per class) – – – 2.07 [1.49–2.88]
Heart rate (per 10 bpm) – – – –
QRS duration (per 10 ms) – 0.97 [0.94–1.00] – –
eGFR (per 10 ml/min) – – – 0.85 [0.76–0.94]
Ischemic etiology – – – –
Hypertension – – – 1.42 [1.04–1.94]
Diabetes mellitus type 2 – – – –
COPD – – – –
Renal failure – 0.73 [0.55–0.98] – 1.93 [1.18–3.16]
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Digoxin was prescribed in one fifth of elderly HFpEF 
patients (20.4%); and ivabradine and amiodarone in very 
few patients, 0.5% and 9.6%, respectively.
The subgroup of HF with supernormal LVEF 
(LVEF > 65%; HFsnEF) in our CHECK-HF octogenarians 
contained only 58 patients (1.7%), see Suppl. Table 7. This 
new entity compromised too small patients group to make 
inferences and was not further included in the analyses.
Discussion
From our Dutch outpatient registry of chronic HF patients, 
we demonstrated that most octogenarians received recom-
mended HF medication, although at lower percentages of 
target doses than previously reported in the entire group, 
except for MRAs [20]. Also, all three of the HF medications 
(beta blocker, RAS inhibitor and MRA) were prescribed in 
only about one quarter of octogenarians with HFrEF. Nota-
bly, women received more often beta blockers and thiazides 
than men.
The guidelines do not recommend specific HF therapies 
in patients with HFmrEF and HF medication did not differ 
significantly from HFrEF patients.
In the HFpEF group aged ≥ 80 years, prescription rates 
of diuretics were higher than 90%. A substantial proportion 
received also a beta blocker, RAS inhibitor or MRA, likely 
to be related to the treatment of prevalent comorbidities. 
Due to clinical referral to out-hospital heart failure clinics, 
irrespective of patients’ age, CHECK-HF contains a rela-
tively high percentage of patients with HFrEF (overall 52% 
and in octogenarians: 58%) in comparison to the prevalence 
of HFpEF in Western populations. Although, the National 
Audit for England and Wales also reported that substan-
tially more HFrEF than HFpEF patients (66.8% and 33.2%, 
respectively) were included in their registry (2016–2017), 
e.g., after a hospital admission for heart failure [21].
Pharmacological therapy
Elderly patients constitute a large part of the HF population 
in Western countries, 1–4 but only few studies addressed 
HF pharmacologic management of patients aged ≥ 80 years 
[11–17]. In the Euro Heart Failure Survey (EHFS) II, both 
mortality rates of octogenarians during hospital stay and 
during follow-up of 12 months were significantly higher 
than in younger patients [12]. Notably, from the consecu-
tive EHFS programs, a gradual improvement, though still 
suboptimal, of medical therapies in octogenarians hospital-
ized for HF was reported. The presence of comorbidities 
predicted mortality and the use of ACE inhibitors and beta 
blockers were associated with better outcome 11, 12]. The 
French OCTOCARDIO study found that even in the absence 
of comorbidity, in elderly patients with HF, ACE inhibitors 
Fig. 3  Percentage of beta blocker, RAS inhibitor and/or MRA use in 
HFrEF and HFmrEF patients aged ≥ 80  years for men and women. 
HFrEF heart failure with reduced ejection fraction, HFmrEF heart 
failure with mid-range ejection fraction, RAS renin–angiotensin sys-
tem, RAS inhibitor angiotensin-converting enzyme (ACE) inhibitor or 
angiotensin receptor blocker (ARB), MRA mineralocorticoid receptor 
antagonists, ESC European Society of Cardiology
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and beta blockers were prescribed to only 40% and 48% of 
patients, respectively, probably because of their advanced 
age alone [13]. Data from a French national observational 
retrospective cohort of 1825 patients aged > 80 years who 
were for the first time hospitalized for HF demonstrated that 
only 5% of them received an optimal treatment at discharge 
(combination of RAS inhibitor, beta blocker and MRA) [14]. 
During their follow-up period of 2 years, only beta-blocker 
prescription levels (p = 0.02) increased. In the CHECK-HF 
registry in chronic HF, about one third of patients were 
aged ≥ 80 years, thus resembling contemporary real-world 
practice in civilized countries. We found higher prescription 
rates of recommended HF medication than in these previous 
registries, which may be related to the delivery of specialist 
outpatient HF care in the vast majority of patients. However, 
in a substantial part of the HFrEF group, the actual dosages 
were lower than in younger patients [20].
Many factors may play a role in suboptimal therapy in 
the very old HF patients. In CHECK-HF, lower rates of 
guideline-directed pharmacotherapy in octogenarians with 
HFrEF were associated with NYHA class, LVEF and comor-
bidities. Lower prescription rates and tolerable dosages of 
recommended HF medication may be attributed to several 
limiting factors, e.g., low blood pressure and renal failure 
[27]. Also, recent data from the CHAMP-HF registry of in 
total 3518 patients from 150 primary care and cardiology 
practices showed that lower medication utilization or dose 
was associated with older age, lower blood pressure, more 
severe functional class, renal insufficiency, and recent HF 
hospitalization [18]. Remarkably, a recent post hoc analy-
sis of the BIOSTAT-CHF study suggested that women with 
HFrEF might need lower doses of RAS inhibitors and beta 
blockers than men, also adjusted for age [22].
The Swedish Heart Failure Registry reported that 80% 
of HFrEF patients with age > 80 years used RAS inhibitors, 
which was associated with reduced morbidity and mortality 
in this observational study [16]. Also, the use of beta block-
ers was associated with improved all-cause and CV survival 
[17]. So, suboptimal use of HF medication may lead to 
worse clinical outcomes. Also, only 40% patients of the total 
HFrEF cohort of that registry (11,215 patients, 27% women; 
mean age 75 ± 11 years) received a MRA [23]. Notably, the 
underuse of MRA was not related to hyperkalaemia, but 
among other factors, to impaired renal function, even in the 
range of a creatinine clearance 30–59.9 ml/min, which is not 
a contraindication for MRA use. Adherence to guideline-
directed therapy of HFrEF, with prescription of at least 50% 
of the target dosage, is associated with better outcome [6, 
24–27]; although, this association has not been proven for 
very elderly HF patients. In the QUALIFY international reg-
istry, mainly younger patients were included and both mean 
age and age ≥ 74 years did not influence adherence to (ESC 
2012) guideline-directed medical therapy in HFrEF patients.
In addition, other age-related factors, particularly frailty, 
cognitive impairment and polypharmacy may contribute 
to suboptimal therapy of elderly HF patients [28]. In pre-
vious randomized clinical trials, patients aged ≥ 75 years 
were underrepresented [7-10]. Consequently, there is no 
conclusive evidence that targeting at high dosages of medi-
cal therapy is equally beneficial in octogenarians compared 
with younger HFrEF patients and this may be another impor-
tant reason for a lower uptake of HF medication in octoge-
narians. Awareness and assessment of comorbidities, and 
adequate management of these, may improve tailored HF 
care of the elderly patients [29]. In addition, reflection on 
optimal management and accepting lower age-adjusted tar-
get, tolerable dose of HF medication in elderly, may also be 
advocated. Accordingly, patient preferences and caregiver 
perceptions may influence therapeutic decisions in older HF 
patients [30].
In HFpEF, there are unmet needs for evidence-based ther-
apies in general and in elderly patients in particular, because 
of the steeply increasing prevalence with age. Interestingly, 
in the Swedish Heart Failure Registry, the use of RAS 
antagonists and beta blockers in HFpEF was associated with 
lower all-cause mortality [31, 32]. However, observational 
associations in HF have limited potential to make reliable 
therapeutic inferences, because (residual) confounding can-
not be excluded [33].
Limitations and strengths
The CHECK-HF registry is a large-scale real-word registry 
of heart failure outpatient clinics in the Netherlands reflec-
tive of Western European countries. However, some limita-
tions should be mentioned, such as the cross-sectional design 
and there were no outcome data collected. In addition, some 
missing data exist, which might influence results. However, 
imputation of missing data in multivariable analyses did not 
influence results. The etiology of heart failure was judged 
by the physician of the participating centers. Our registry 
included only patients seen in secondary, but not in primary 
care, which limits the generalizability of our findings to the 
primary care setting. Data on high age-related factors, e.g., 
frailty, cognitive impairment, dementia and disability were 
not collected, which may limit the understanding of the rea-
son of not following the guidelines. Hardly any informa-
tion was available for the use of sacubitril/valsartan, since 
it was approved in the Netherlands only in June 2016. Also, 
the use of oral nitrates (isosorbide-dinitrate or isosorbide-
mononitrate) combined with hydralazine is so low in the 
Netherlands that data was not collected. Strengths of the 
study are the reflection of the true practice of nationwide 
out-patient HF management and the high percentages of 
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elderly patients with detailed information on medication 
prescription and dosage.
Conclusion
In this Dutch real-world registry of outpatient HF popula-
tion, the majority of octogenarians received evidence-based 
HF medication, but at lower doses than recommended and 
only a minority received all three of the HF medication 
(beta blocker, RAS inhibitor (ACE inhibitor or ARB) and 
MRA). Analyses of clinical variables, including higher rates 
of comorbidities and reported contraindications and toler-
ances, did not fully explain the underuse of recommended 
HF therapies in octogenarians with HFrEF. Thus, future 
research should lead to strategies to improve management 
of elderly HF patients. Both in the HFmrEF group and the 
HFpEF group, in which evidence-based therapies are lack-
ing, prescription rates of diuretics were also high and a sub-
stantial part of them received a beta blocker, RAS inhibitor 
and MRA.
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